Lutetium-177 PSMA radioligand therapy — the targeted radionuclide treatment delivering beta-emitting Lu-177 directly to prostate-specific membrane antigen-expressing prostate cancer cells — represents the most commercially significant radiopharmaceutical theranostics launch in the market's history, with the Radiopharmaceutical Theranostics Market reflecting Lu-177 PSMA as the...

The nuclear medicine market is entering a period of steady expansion as healthcare systems increasingly adopt precision diagnostics and targeted therapies. The market was valued at USD 21.3 billion in 2025 and is projected to reach USD 38.2 billion by 2033, growing at a 6.8% CAGR from 2026 to 2033. The market is estimated to reach USD 24.1 billion in 2026. Growth is being supported by a robust...